Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730000 | 0.94 | KDM4E (0.63) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL1045292 | 0.91 | SIRT6 (0.69) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL10511652 | 0.86 | LMNA (0.68) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL5187796 | 0.85 | SIRT6 (0.60) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL5743368 | 0.85 | HTR1A (0.61) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL4507337 | 0.85 | SIRT6 (0.60) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL374222 | 0.84 | SIRT6 (0.68) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL5209234 | 0.84 | MAPT (0.67) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL3187195 | 0.84 | SIRT6 (0.59) | SIRT6LMNAHTR1APOLBMAPT | |
| SCHEMBL12431530 | 0.83 | MAPT (0.70) | SIRT6LMNAHTR1APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102079746-A | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2011-06-01 | — | — | CN | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| CN-101454326-A | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-06-10 | — | — | CN | disclosed |
| CN-1826343-A | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | PHARMACIA ITALIA SPA (IT) | 2006-08-30 | — | — | CN | disclosed |
| EP-0889881-B1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | NAEJA PHARMACEUTICAL INC (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-6153616-A | Triazoles as therapeutic agents for fungal infections | SYNPHAR LABORATORIES, INC. (CA) | 2000-11-28 | — | — | US | disclosed |
| EP-0889881-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES INC. (CA) | 1999-01-13 | — | — | EP | disclosed |
| WO-1998031675-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES, INC. (US) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | SIRT6 262/4885LMNA 3803/4885HTR1A 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.